1.301 - 1.325 of 57.080
- Product
- Maturity
- Leverage (Omega)
- Sell
- Buy
- Nike Call 76,00 21 Jan 2028
- Goldman Sachs
- 21.01.28
- 2,92x
- Analysis
- Nike Call 64,00 21 Jan 2028
- Goldman Sachs
- 21.01.28
- 2,77x
- Analysis
- Nike Call 66,00 21 Jan 2028
- Goldman Sachs
- 21.01.28
- 2,76x
- Analysis
- Nike Call 82,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,31x
- Analysis
- Nike Call 86,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,35x
- Analysis
- Nike Call 58,00 21 Jan 2028
- Goldman Sachs
- 21.01.28
- 2,64x
- Analysis
- Nike Call 80,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,32x
- Analysis
- Novo Nordisk Call 340,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 2,88x
- Analysis
- Nike Call 78,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,32x
- Analysis
- Nike Call 72,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,20x
- Analysis
- Nike Call 58,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 2,92x
- Analysis
- Nike Call 84,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,40x
- Analysis
- Nike Call 56,00 21 Jan 2028
- Goldman Sachs
- 21.01.28
- 2,65x
- Analysis
- Nike Call 56,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 2,90x
- Analysis
- Nike Call 68,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,14x
- Analysis
- Nike Call 60,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 2,98x
- Analysis
- Nike Call 70,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,21x
- Analysis
- Nike Call 66,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,12x
- Analysis
- Novo Nordisk Call 380,00 19 Mar 2027
- Goldman Sachs
- 19.03.27
- 3,53x
- Analysis
- Novo Nordisk Call 360,00 19 Mar 2027
- Goldman Sachs
- 19.03.27
- 3,37x
- Analysis
- Nike Call 64,00 17 Sep 2027
- Goldman Sachs
- 17.09.27
- 3,09x
- Analysis
- Nike Call 86,00 17 Jun 2027
- Goldman Sachs
- 17.06.27
- 3,64x
- Analysis
- Nike Call 68,00 17 Jun 2027
- Goldman Sachs
- 17.06.27
- 3,50x
- Analysis
- Novo Nordisk Call 290,00 19 Mar 2027
- Goldman Sachs
- 19.03.27
- 2,79x
- Analysis
- Nike Call 72,00 17 Jun 2027
- Goldman Sachs
- 17.06.27
- 3,53x
- Analysis